QNCXQuince Therapeutics, Inc.

QNCX Stock Price, Valuation & Chart | Quince Therapeutics, Inc.

Compare

$32.150+0.04 (+0.12%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology QNCX intrinsic value QNCX calculated fair value vs price

Overview Financials Dividends Ratios

QNCX Historical price chart

QNCX Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization8.95M

PE Ratio-0.3

EPS-106.2

Trading Volume15.46K

Today's High/Low33.07/31.94

Dividend Yield0.00

52 Week High/Low910.0/15.1

Shares Outstanding278.41K

QNCX Financial Statement

QNCX Analyst ratings

QNCX Analysis & performance metrics

QNCX Company profile

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad…

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to…

QNCX Management team

Name

Position

Pamela M. Williamson FRAPS, M.B.A., RAC

Head of Regulatory Affairs

Guenter R. Janhofer M.D., Ph.D.

Chief Scientific Officer

Dirk Thye M.D.CEO

Chief Executive Officer, Chief Medical Officer & Director

Brendan Hannah M.B.A.COO

Chief Business Officer, Chief Operating Officer, Chief Compliance Officer and Principal Financial & Accounting Officer

Stacy Roughan

Vice President of Corporate Communications & Investor Relations

Mary Ellen Sillivos

Vice President of Human Resources

Stewart A. Low Ph.D.

Head of Discovery

Giovanni Mambrini M.Sc.CTO

Chief Technology Officer

Name

Position

Pamela M. Williamson FRAPS, M.B.A., RAC

Head of Regulatory Affairs

Guenter R. Janhofer M.D., Ph.D.

Chief Scientific Officer

Dirk Thye M.D.CEO

Chief Executive Officer, Chief Medical Officer & Director

Brendan Hannah M.B.A.COO

Chief Business Officer, Chief Operating Officer, Chief Compliance Officer and Principal Financial & Accounting Officer

Stacy Roughan

Vice President of Corporate Communications & Investor Relations

Mary Ellen Sillivos

Vice President of Human Resources

Stewart A. Low Ph.D.

Head of Discovery

Giovanni Mambrini M.Sc.CTO

Chief Technology Officer

Management Team

Pamela M. Williamson FRAPS, M.B.A., RAC

Head of Regulatory Affairs

Guenter R. Janhofer M.D., Ph.D.

Chief Scientific Officer

Dirk Thye M.D.CEO

Chief Executive Officer, Chief Medical Officer & Director

Brendan Hannah M.B.A.COO

Chief Business Officer, Chief Operating Officer, Chief Compliance Officer and Principal Financial & Accounting Officer

Stacy Roughan

Vice President of Corporate Communications & Investor Relations

Mary Ellen Sillivos

Vice President of Human Resources

Stewart A. Low Ph.D.

Head of Discovery

Giovanni Mambrini M.Sc.CTO

Chief Technology Officer

Management

Pamela M. Williamson FRAPS, M.B.A., RAC

Head of Regulatory Affairs

Guenter R. Janhofer M.D., Ph.D.

Chief Scientific Officer

Dirk Thye M.D.CEO

Chief Executive Officer, Chief Medical Officer & Director

Brendan Hannah M.B.A.COO

Chief Business Officer, Chief Operating Officer, Chief Compliance Officer and Principal Financial & Accounting Officer

Stacy Roughan

Vice President of Corporate Communications & Investor Relations

Mary Ellen Sillivos

Vice President of Human Resources

Stewart A. Low Ph.D.

Head of Discovery

Giovanni Mambrini M.Sc.CTO

Chief Technology Officer

Total 8 executives

QNCX Frequently asked questions

What is Quince Therapeutics, Inc. (QNCX) Stock Price?

Current stock price of Quince Therapeutics, Inc. (QNCX) stock is $32.150. The stock price is +0.12% higher in the session. The intraday range can be seen from this page. Volume of Quince Therapeutics, Inc. (QNCX) stock is 15.46K.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Quince Therapeutics, Inc. (QNCX) stock price going up or down today?

The stock price of Quince Therapeutics, Inc. (QNCX) can change with earnings, company news, and overall market sentiment. Quince Therapeutics, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Quince Therapeutics, Inc. stock expensive at its current price?

Whether Quince Therapeutics, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for QNCX on this page is -0.30. EPS on this page is -106.20. Compare those figures with peers and growth expectations before deciding if the current Quince Therapeutics, Inc. price is justified.

How has the stock price of Quince Therapeutics, Inc. (QNCX) performed historically?

Historical performance for Quince Therapeutics, Inc. (QNCX) is shown on the price chart on this page. Review multi-period moves alongside volume to see how QNCX reacted to past earnings and market events.

Should I buy Quince Therapeutics, Inc. (QNCX) stock, at this price?

Buying Quince Therapeutics, Inc. (QNCX) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.